Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ovicidal efficacy trial of three head lice products in primary school-aged children
ACTRN12609000884202Phase 4Completed
- Sponsor
- Key Pharmaceuticals Ltd
- Start
- Oct 2009
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of neutralice advance and MOOV Lotion in pediculosis capitis (3 arms), sponsored by Key Pharmaceuticals Ltd. Primary endpoints: Ovicidal efficacy index (OEI) and Egg hatch proportion after incubation. Started Oct 2009; status: completed.
02
Drugs
neutralice advanceMOOV Lotion
03
Conditions
pediculosis capitis
Beyond the preview
Go deeper on ACTRN12609000884202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000884202.